Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLOW2: Glycopyrronium Bromide in COPD
NCT00929110Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jun 2009; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00929110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00929110.